Department of Obstetrics and Gynecology, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki city, Osaka, 569-8686, Japan.
J Ovarian Res. 2012 Nov 1;5(1):31. doi: 10.1186/1757-2215-5-31.
The resistance of endometriotic tissue to progesterone can be explained by alterations in the distribution of progesterone receptor (PR) and estrogen receptor (ER) isoforms. The aims of this study were to examine the expressions of PR-A, PR-B, ERα and ERβ in endometrioma and assess whether these expressions are affected by dienogest or leuprolide acetate (LA) treatment.
We enrolled 60 females, including 43 patients with endometriosis (14 who received no medical treatment, 13 who received dienogest and 16 who received LA before undergoing laparoscopic surgery) and 17 patients with leiomyoma. The expression levels of PR and ER isoforms in eutopic and ectopic endometrium were assayed with quantitative real-time PCR, and confirmed with immunohistochemistry.
A decreased PR-B/PR-A ratio and an increased ERβ/ERα ratio were demonstrated in ectopic endometrium derived from females with endometriosis compared with the ratios observed in eutopic endometrium obtained from females without endometriosis. Although LA treatment did not affect the PR-B/PR-A and ERβ/ERα ratios, dienogest treatment increased the PR-B/PR-A ratio and decreased the ERβ/ERα ratio in patients with endometriomas.
Dienogest may improve progesterone resistance in endometriotic tissue by increasing the relative expressions of PR-B and PR-A, and decreasing the relative expressions of ERβ and ERα.
子宫内膜异位症组织对孕激素的抵抗可以通过孕激素受体(PR)和雌激素受体(ER)亚型分布的改变来解释。本研究的目的是检测在位和异位子宫内膜中 PR-A、PR-B、ERα 和 ERβ 的表达,并评估这些表达是否受地诺孕素或亮丙瑞林治疗的影响。
我们纳入了 60 名女性,包括 43 名子宫内膜异位症患者(14 名未接受任何治疗,13 名接受地诺孕素治疗,16 名接受亮丙瑞林治疗)和 17 名子宫肌瘤患者。通过实时定量 PCR 检测在位和异位子宫内膜中 PR 和 ER 亚型的表达水平,并通过免疫组织化学法进行验证。
与无子宫内膜异位症的女性在位子宫内膜相比,子宫内膜异位症患者的异位子宫内膜中 PR-B/PR-A 比值降低,ERβ/ERα 比值升高。虽然亮丙瑞林治疗不影响 PR-B/PR-A 和 ERβ/ERα 比值,但地诺孕素治疗可增加子宫内膜异位症患者的 PR-B/PR-A 比值,降低 ERβ/ERα 比值。
地诺孕素可能通过增加 PR-B 和 PR-A 的相对表达,降低 ERβ 和 ERα 的相对表达,改善子宫内膜异位症组织中的孕激素抵抗。